Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03736447
Other study ID # ARC005
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 27, 2018
Est. completion date July 5, 2022

Study information

Verified date February 2023
Source Aimmune Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to < 4 years.


Description:

This is a Phase 3, randomized, double-blind, placebo-controlled study conducted at 14 study sites in North America and 9 in Europe to evaluate the efficacy and safety of AR101 in a characterized oral desensitization immunotherapy (CODITâ„¢) regimen compared with placebo in peanut-allergic children aged 1 to < 4 years.


Recruitment information / eligibility

Status Completed
Enrollment 146
Est. completion date July 5, 2022
Est. primary completion date July 5, 2022
Accepts healthy volunteers No
Gender All
Age group 1 Year to 3 Years
Eligibility Inclusion Criteria: - Aged 1 to < 4 years at randomization. - Written informed consent from the legal guardian/parent (or both parents where required by local authorities). Provide assent where required and as appropriate per local requirements. - Sensitivity to peanut, defined as one of the following: - No known history of peanut ingestion and has serum IgE to peanut = 5 kUA/L within 12 months before randomization. - Documented history of physician-diagnosed IgE-mediated peanut allergy that includes the onset of characteristic* signs and symptoms of allergy within 2 hours of known oral exposure to peanut or peanut-containing food, and has a mean wheal diameter on skin prick test (SPT) to peanut of at least 3 mm greater than the negative control (diluent) or serum IgE to peanut = 0.35 kUA/L, obtained within 12 months before randomization. - Development of age-appropriate dose-limiting allergy symptoms after consuming single doses of peanut protein > 3 mg to = 300 mg in a screening DBPCFC. - A palatable vehicle food to which the subject is not allergic must be available for administering study product. Exclusion Criteria: - History of severe or life-threatening anaphylaxis anytime before the screening DBPCFC. - History of hemodynamically significant cardiovascular or renovascular disease, including uncontrolled or inadequately controlled hypertension. - History of biopsy-confirmed diagnosis of EoE; other eosinophilic GI disease; chronic, recurrent, or severe gastroesophageal reflux disease (GERD); or symptoms of dysphagia (eg, difficulty swallowing, food "getting stuck"). - Recurrent GI symptoms considered clinically significant in the opinion of the investigator. - History of a mast cell disorder including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (eg, cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema. - Moderate or severe persistent asthma (criteria steps 3-6; National Heart, Lung, and Blood Institute [NHLBI], 2007). - Mild asthma (criteria steps 1-2; NHLBI, 2007) that is uncontrolled or difficult to control based on NHLBI 2007 criteria. - History of high-dose corticosteroid use (eg, 1-2 mg/kg prednisone or equivalent for > 3 days) by any route of administration as defined by any of the following: - Steroid administered daily for > 1 month within 1 year before screening - One steroid course within 6 months before screening - More than 2 steroid courses = 1 week in duration within 1 year before screening - History of food protein-induced enterocolitis syndrome (FPIES) within 12 months before screening. - Recurrent urticaria. - History of failure to thrive or any other form of abnormal growth, or developmental or speech delay that precludes age-appropriate communication. - History of chronic disease (except mild intermittent asthma, mild persistent asthma that is controlled, atopic dermatitis, or allergic rhinitis) that is or is at significant risk of becoming unstable or requiring a change in a chronic therapeutic regimen. - Unable to discontinue antihistamines and other medications that could interfere with the assessment of an allergic reaction for 5 half-lives of the medication before the screening SPT, first day of dose escalation, and DBPCFCs. - Use or anticipated use of a prohibited medication (eg, beta blockers [oral], angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, or tricyclic antidepressants), monoclonal antibody, or any other immunomodulatory therapy (including immunosuppressive medications). - Treatment with any form of immunotherapy for any food allergy anytime before screening. - Participation in another clinical trial within 30 days or 5 half-lives of the investigational product, whichever is longer, before screening. - Allergy to oat or rice. - Hypersensitivity to epinephrine or any of the excipients in the epinephrine auto-injector. - Parent/caregiver unable or unwilling to use epinephrine auto-injectors. - Unable to follow the protocol requirements. - Any other condition (concurrent disease, infection, comorbidity, or psychiatric or psychological disorders) or reason that may interfere with the ability to participate in the study, cause undue risk, or complicate the interpretation of data, in the opinion of the investigator or medical monitor. - Resides at the same place as another subject in any AR101 interventional trial. - Lives in the same household and/or is a family member of a sponsor employee or site staff involved in conducting this study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
AR101 powder provided in capsules & sachets
Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
Placebo powder provided in capsules & sachets
Study product formulated to contain only inactive ingredients for use as defined in the protocol

Locations

Country Name City State
France Jeanne de Flandre Hospital Lille
Germany Charité Universitaetsmedizin Berlin Berlin
Germany University of Frankfurt Frankfurt am Main
United Kingdom James Paget University Hospital Gorleston-on-Sea Norfolk
United Kingdom Leicester Royal Infirmary Leicester
United Kingdom Guy's and St. Thomas' NHS Foundation Trust, Snowy Owl, First Floor, Evelina Children's Hospital London
United Kingdom Royal Manchester Children's Hospital Central Manchester University Hospitals Manchester
United Kingdom Sheffield Children's Hospital Sheffield
United Kingdom University Hospital Southampton Foundation NHS Trust Southampton General Hospital Southampton
United States University of Michigan Division of Allergy and Clinical Immunology Ann Arbor Michigan
United States Children's Center for Advanced Pediatrics Clinical Research Lab Atlanta Georgia
United States The John Hopkins Hospital Baltimore Maryland
United States UNC-CH School of Medicine, Pediatric Allergy, Immunology & Rheumatology, Food Allergy Chapel Hill North Carolina
United States Clinical Research of Charlotte Charlotte North Carolina
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Arkansas Children's Hospital Little Rock Arkansas
United States Atlanta Allergy & Asthma Clinic Marietta Georgia
United States Sean N. Parker Center for Allergy & Asthma Reseach, LPCH at El Camino Hospital Mountain View California
United States Icahn School of Medicine at Mount Sinai New York New York
United States Atlantic Research Center Ocean City New Jersey
United States Peninsula Research Associates, Inc. Rolling Hills Estates California
United States Allergy & Asthma Medical Group and Research Center San Diego California
United States Virginia Mason Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Aimmune Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  France,  Germany,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Subjects Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) The percentage of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild allergy symptoms during the exit double-blind placebo-controlled food challenge (DBPCFC). 12 months
Secondary Percentage of Subjects Who Tolerated a Single Highest Dose of at Least 1000 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) [Time Frame: 12 Months] The percentage of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild allergy symptoms during the exit double-blind placebo-controlled food challenge (DBPCFC). 12 months
Secondary Percentage of Subjects Who Tolerated a Single Highest Dose of at Least 300 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) The percentage of subjects in the ITT population who achieve desensitization as determined by tolerating specified challenge doses of peanut protein with no more than mild allergy symptoms during the exit double-blind placebo-controlled food challenge (DBPCFC). 12 months
Secondary Maximum Severity of Symptoms in Participants at Any Challenge Dose During the Exit Double-blind Placebo Controlled Food Challenge (DBPCFC) The maximum severity of symptoms that occurred at any challenge dose of peanut protein during the exit DBPCFC. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05667610 - Immune-supportive Diet and Gut Permeability in Allergic Children N/A
Recruiting NCT05440643 - Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Phase 1
Terminated NCT03849079 - Validation of the HYPONUT Product N/A
Completed NCT02979600 - Clinical and Biological Efficacy of Peanut Oral Immunotherapy N/A
Completed NCT01955109 - Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Phase 2
Completed NCT01950533 - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Recruiting NCT04415593 - High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety N/A
Active, not recruiting NCT04511494 - Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Active, not recruiting NCT04881773 - Oral Low Doses Tolerance INduction Study for Peanuts
Completed NCT03682770 - Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Phase 2
Terminated NCT03703791 - Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents Phase 3
Completed NCT02916446 - Safety Study of Viaskin Peanut to Treat Peanut Allergy Phase 3
Active, not recruiting NCT02402231 - Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Phase 2
Completed NCT03337542 - AR101 Real-World Open-Label Extension Study Phase 3
Recruiting NCT05476497 - Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects Phase 1
Completed NCT03648320 - The Grown Up Peanut Immunotherapy Study N/A
Completed NCT03292484 - Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Phase 3
Completed NCT03852342 - Reactive Doses and Times During Oral Food Challenge to Peanut
Recruiting NCT05138757 - Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Phase 1/Phase 2